Sun Pharma gets approval to sell generic Wegovy in India

Sun Pharmaceutical has received regulatory approval to manufacture and sell a generic version of Wegovy in India and will market the semaglutide product as Noveltreat once the semaglutide patent expires in March 2026.

Sun Pharmaceutical Industries said it has received regulatory approval to manufacture and sell a generic version of the weight-loss drug Wegovy in India. The company will market the generic semaglutide under the brand name Noveltreat once the semaglutide patent expires in March 2026. Indian generic makers are preparing to enter the growing weight-loss market ahead of the patent expiry. Sun Pharma is the second Indian firm to obtain regulatory permission for generic semaglutide. Key details: - The regulator approved Sun Pharma to make and sell generic semaglutide in India. - Sun Pharma plans to launch the product as Noveltreat after the semaglutide patent expires in March 2026. - The article mentions semaglutide is the active ingredient in Novo Nordisk's Wegovy and Ozempic. - Dr Reddy's Laboratories earlier received approval to manufacture and sell a generic version of Ozempic. - Indian manufacturers are seeking approvals ahead of the patent expiry to enter the weight-loss market. Summary: The approvals signal that generic semaglutide will be introduced in India under Sun Pharma's Noveltreat brand following the March 2026 patent expiry. Multiple Indian companies have secured or sought regulatory nods in the same space. The next scheduled milestone is the semaglutide patent expiration in March 2026, after which launches are planned.